FilingReader Intelligence
Xianju Pharmaceutical fined for monopoly violations
May 5, 2025 at 05:10 PM UTC•By FilingReader AI
Zhejiang Xianju Pharmaceutical (SZSE:002332) has announced it received an administrative penalty decision from the Tianjin Market Supervision and Administration Commission regarding violations of China's Anti-Monopoly Law. The commission determined that the company engaged in monopolistic agreements with competitors to manipulate and fix the price of dexamethasone sodium phosphate API.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:002332•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Zhejiang Xianju Pharmaceutical publishes news
Free account required • Unsubscribe anytime